AroCell appoints new CFO - Arocell TK 210 ELISA

Ellen Dittberner will take over as Chief Finance Officer (CFO) at AroCell from August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has great experience, which includes driving change and development processes.

Ellen has extensive experience in several different areas such as Group Accounting, Controlling, and Change Management. As CFO, Ellen will be responsible for AroCell Group's finances with associated processes and personnel.

Lars Jakobsson will continue in his current role until Ellen takes office and thereafter continue to support AroCell in an advisory role as a consultant, to ensure the continuity of the AroCell Group's finance function and be responsible for a transfer to Ellen.

“I am very happy to be able to welcome Ellen as our new CFO at AroCell and look forward to working with her. Ellen's extensive expertise will be a great asset for AroCell in our continued work to grow and develop the company. I would also like to thank Lars for his efforts as CFO. With his solid competence and experience, he has contributed to the business for over 10 years,” says Anders Hultman, AroCells CEO.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com